Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma

A 42-year-old woman with reversible splenial lesion syndrome (RESLES) and rectal adenocarcinoma presented with sudden-onset delirium after the sixth cycle of her chemotherapy drug, oral tegafur-uracil (300 mg/m/day, days 1-14, with treatment cycle repeated every 21 days). Accompanied by the anti-CV2 antibody, paraphasia, and a loss of bimanual coordination, the patient's etiology and clinical manifestations of RESLES are unlike those of other reported cases of RESLES. Tegafur-uracil is an oral fluoropyrimidine that has a similar effect to 5-fluorouracil as an adjuvant treatment for colorectal cancer. The possibility that the toxicity of chemotherapeutic drugs may play a role in the pathogenesis of cytotoxic edema in the splenium of the corpus callosum and extracallosal white matter should be investigated further.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:33

Enthalten in:

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology - 33(2020), 4 vom: 01. Dez., Seite 283-287

Sprache:

Englisch

Beteiligte Personen:

Ge, Yu-Xing [VerfasserIn]
Lin, Ying-Ying [VerfasserIn]
Bi, Qian-Qian [VerfasserIn]
Chen, Yu-Juan [VerfasserIn]

Links:

Volltext

Themen:

1548R74NSZ
Antimetabolites, Antineoplastic
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Tegafur

Anmerkungen:

Date Completed 19.02.2021

Date Revised 19.02.2021

published: Print

Citation Status MEDLINE

doi:

10.1097/WNN.0000000000000250

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM318303698